<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089543</url>
  </required_header>
  <id_info>
    <org_study_id>E3810-J081-204</org_study_id>
    <nct_id>NCT01089543</nct_id>
  </id_info>
  <brief_title>A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blind Study of E3810 for Japanese Subjects With Functional Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of rabeprazole compared to
      placebo in Japanese subjects with Functional Dyspepsia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Complete Dyspepsia Symptom Relief</measure>
    <time_frame>Up to 8 Weeks (including 7 days prior)</time_frame>
    <description>The rate of complete dyspepsia symptom relief according to the Dyspepsia Symptom Questionnaire (DSQ) was defined as a score of 1 for all four major dyspeptic symptoms at week 8 and according to the diary defined as all four dyspepsia symptoms recorded absent during the 7 days prior to week 8. Values presented as percentage of participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Satisfactory Symptom Relief</measure>
    <time_frame>Up to 8 Weeks (including 7 days prior)</time_frame>
    <description>The rate of satisfactory symptom relief according to the DSQ defined as scores of &lt;= 2 for all four major dyspepsia symptoms at week 8 and the diary recordings defined as a frequency of &lt;= 1 day for all four major dyspepsia symptoms during the 7 days before week 8. Lastly, treatment success according to the participants' impression questionnaire where participants answered &quot;yes&quot; or &quot;no&quot; when asked if given the choice, whether they would want to continue to take the study drug after clinical trial completion. Values presented as percentage of participants.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">338</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Rabeprazole 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rabeprazole 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rabeprazole 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole</intervention_name>
    <description>Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
    <arm_group_label>Rabeprazole 10 mg</arm_group_label>
    <other_name>E3810</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole</intervention_name>
    <description>Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
    <arm_group_label>Rabeprazole 20 mg</arm_group_label>
    <other_name>E3810</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole</intervention_name>
    <description>Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
    <arm_group_label>Rabeprazole 40 mg</arm_group_label>
    <other_name>E3810</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>E3810</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        -Participants diagnosed as Functional Dyspepsia according to Rome III criteria.

        Exclusion criteria:

          -  Participants with neuropsychiatric disorder.

          -  Participants diagnosed with irritable bowel syndrome, inflammatory bowel disease and
             serious constipation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoshiumi Okubo</last_name>
    <role>Study Director</role>
    <affiliation>Eisai Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chikushino</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tsuchiura</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takamatsu</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yufu</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nakagami</city>
        <state>Okinawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moriguchi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karatsu</city>
        <state>Saga</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kusatsu</city>
        <state>Shiga</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izumo</city>
        <state>Shimane</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fujieda</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Otawara</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimotsuga</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bunkyo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mitaka</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nakano</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ota</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Setagaya</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shibuya</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinagawa</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <results_first_submitted>September 17, 2013</results_first_submitted>
  <results_first_submitted_qc>September 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 19, 2013</results_first_posted>
  <last_update_submitted>November 27, 2013</last_update_submitted>
  <last_update_submitted_qc>November 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dyspepsia</keyword>
  <keyword>rabeprazole</keyword>
  <keyword>Japan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was recruited at 66 centers in Japan during the period of 21-April-2010 to 12-Aug-2011.</recruitment_details>
      <pre_assignment_details>Participants were initially enrolled into a 1- or 2-week run-in period (single-blinded administration of placebo). Participants who did not respond to placebo were randomized to an 8-week treatment period (double-blinded administration) of rabeprazole 10 mg, 20 mg, 40 mg, or placebo, once daily after breakfast.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rabeprazole 10 mg</title>
          <description>Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Rabeprazole 20 mg</title>
          <description>Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Rabeprazole 40 mg</title>
          <description>Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="85"/>
                <participants group_id="P3" count="84"/>
                <participants group_id="P4" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="81"/>
                <participants group_id="P4" count="83"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Per Protocol Set (PPS): was defined as those participants who complied with the study protocol. N= 338 participants were enrolled at study start. However, a total of 307 participants were included in PPS for efficacy evaluation.</population>
      <group_list>
        <group group_id="B1">
          <title>Rabeprazole 10 mg</title>
          <description>Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Rabeprazole 20 mg</title>
          <description>Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Rabeprazole 40 mg</title>
          <description>Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="74"/>
            <count group_id="B4" value="80"/>
            <count group_id="B5" value="307"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.9" spread="14.9"/>
                    <measurement group_id="B2" value="50.2" spread="16.5"/>
                    <measurement group_id="B3" value="46.4" spread="14.8"/>
                    <measurement group_id="B4" value="45.8" spread="15.5"/>
                    <measurement group_id="B5" value="47.3" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Complete Dyspepsia Symptom Relief</title>
        <description>The rate of complete dyspepsia symptom relief according to the Dyspepsia Symptom Questionnaire (DSQ) was defined as a score of 1 for all four major dyspeptic symptoms at week 8 and according to the diary defined as all four dyspepsia symptoms recorded absent during the 7 days prior to week 8. Values presented as percentage of participants.</description>
        <time_frame>Up to 8 Weeks (including 7 days prior)</time_frame>
        <population>Per Protocol Set (PPS) population defined as those participants who complied with the study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabeprazole 10 mg</title>
            <description>Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rabeprazole 20 mg</title>
            <description>Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rabeprazole 40 mg</title>
            <description>Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Complete Dyspepsia Symptom Relief</title>
          <description>The rate of complete dyspepsia symptom relief according to the Dyspepsia Symptom Questionnaire (DSQ) was defined as a score of 1 for all four major dyspeptic symptoms at week 8 and according to the diary defined as all four dyspepsia symptoms recorded absent during the 7 days prior to week 8. Values presented as percentage of participants.</description>
          <population>Per Protocol Set (PPS) population defined as those participants who complied with the study protocol.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DSQ (n= 76, n= 75, n= 74, n= 78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4"/>
                    <measurement group_id="O2" value="29.3"/>
                    <measurement group_id="O3" value="27.0"/>
                    <measurement group_id="O4" value="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diary Recordings (n= 77, n= 76, n=74, n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1"/>
                    <measurement group_id="O2" value="28.9"/>
                    <measurement group_id="O3" value="27.0"/>
                    <measurement group_id="O4" value="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Satisfactory Symptom Relief</title>
        <description>The rate of satisfactory symptom relief according to the DSQ defined as scores of &lt;= 2 for all four major dyspepsia symptoms at week 8 and the diary recordings defined as a frequency of &lt;= 1 day for all four major dyspepsia symptoms during the 7 days before week 8. Lastly, treatment success according to the participants' impression questionnaire where participants answered &quot;yes&quot; or &quot;no&quot; when asked if given the choice, whether they would want to continue to take the study drug after clinical trial completion. Values presented as percentage of participants.</description>
        <time_frame>Up to 8 Weeks (including 7 days prior)</time_frame>
        <population>Per Protocol Set (PPS) Population: defined as those participants who complied with the study protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Rabeprazole 10 mg</title>
            <description>Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Rabeprazole 20 mg</title>
            <description>Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Rabeprazole 40 mg</title>
            <description>Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Satisfactory Symptom Relief</title>
          <description>The rate of satisfactory symptom relief according to the DSQ defined as scores of &lt;= 2 for all four major dyspepsia symptoms at week 8 and the diary recordings defined as a frequency of &lt;= 1 day for all four major dyspepsia symptoms during the 7 days before week 8. Lastly, treatment success according to the participants' impression questionnaire where participants answered &quot;yes&quot; or &quot;no&quot; when asked if given the choice, whether they would want to continue to take the study drug after clinical trial completion. Values presented as percentage of participants.</description>
          <population>Per Protocol Set (PPS) Population: defined as those participants who complied with the study protocol.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
                <count group_id="O3" value="74"/>
                <count group_id="O4" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DSQ (n=76, n=75, n=74, n=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1"/>
                    <measurement group_id="O2" value="45.3"/>
                    <measurement group_id="O3" value="39.2"/>
                    <measurement group_id="O4" value="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diary Recordings (n=77, n=76, n=74, n=80)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7"/>
                    <measurement group_id="O2" value="48.7"/>
                    <measurement group_id="O3" value="39.2"/>
                    <measurement group_id="O4" value="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Success (n=76, n=75, n=74, n=78)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4"/>
                    <measurement group_id="O2" value="85.3"/>
                    <measurement group_id="O3" value="64.9"/>
                    <measurement group_id="O4" value="59.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 8 weeks</time_frame>
      <desc>Safety Analysis Set was defined as those participants who received at least one dose of study drug (N= 338). One participant was incorrectly assigned to a different dose group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rabeprazole 10 mg</title>
          <description>Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Rabeprazole 20 mg</title>
          <description>Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Rabeprazole 40 mg</title>
          <description>Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Blood Triglycerides Increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yoshiumi Okubo, Study Director</name_or_title>
      <organization>Eisai Inc.</organization>
      <phone>+81-3-3817-3908</phone>
      <email>y4-okubo@hhc.eisai.co.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

